The effects of PEGylation on LNP based mRNA delivery to the eye
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Gene therapy is now an effective approach to treat many forms of retinal degeneration. Delivery agents that are cell-specific, allow for multiple dosing regimens, and have low immunogenicity are needed to expand the utility of gene therapy for the retina. We generated eight novel lipid nanoparticles (LNPs) ranging in size from 50 nm to 150 nm by changing the PEG content from 5% to 0.5%, respectively. Subretinal injections of LNP-mRNA encoding luciferase revealed that 0.5% PEG content within nanoparticles elicits the highest expression. Similar injections of LNP delivered cre mRNA into Ai9 mice revealed cell-specific protein expression in the retinal pigment epithelium (RPE), confirmed by fundus photography and immunohistochemistry of whole globe cross-sections. To investigate mechanisms of LNP delivery to the eye, we injected mCherry mRNA using the subretinal approach in apoE-/- and Mertk-/- mice. RPE transfection was observed in both mouse models suggesting that LNP intracellular delivery is not solely dependent on apolipoprotein adsorption or phagocytosis. To investigate LNP penetration, particles were delivered to the vitreous chamber via an intravitreal injection. The 0.5% PEG particles mediated the highest luciferase activity and expression was observed in the Müller glia, the optic nerve head and the trabecular meshwork, but failed to reach the RPE. Overall, particles containing less PEG (~150 nm in size) mediated the highest expression in the eye. Thus far, these particles successfully transfect RPE, Müller cells, the optic nerve head and the trabecular meshwork based on route of administration which can expand the utility of LNP-mediated gene therapies for the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, lipid-based transfection systems have shown success in their ability to transfer the target genes into retinal cells in several studies, and multiple lipid-based drugs for eye diseases are already available in the clinic35,79,87–91 and for the delivery of CRISPR or ribonucleoproteins for base editing.92,93”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [90]
Experimental — accuracy not yet measuredIn the citing paper
“The PEG-molecules at the surface prevent the individual LNPs from aggregating.”
From mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability (2021) · cites this paper as Ryals et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907
Cellular uptake of nanoparticles: Journey inside the cell
Behzadi, S., Serpooshan, V., Tao, W., Hamaly, M. A., Alkawareek, M. Y., Dreaden, E. C., Brown, D., Alkilany, A. M., Farokhzad, O. C., & Mahmoudi, M. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00636a · Cited by 2,859 · cited 2×
“In general, particles<500 nm are internalized via endocytosis, whereas particles >1000 nm utilize phagocytosis [22, 23].”
BackgroundResultEngineered nanoparticles interacting with cells: size matters
Shang, L., Nienhaus, K., & Nienhaus, G. U. (2014) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-12-5 · Cited by 1,316
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · cited 3×
“This was established by observing diminished LNP transfection efficiency in both apoE and LDLR mice [27].”
BackgroundLipid Nanoparticle Systems for Enabling Gene Therapies
Cullis, P. R., & Hope, M. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.013 · Cited by 1,208
(1984) · PubMed · Cited by 1,200
Pharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693
Müller glial cell reprogramming and retina regeneration
Goldman, D. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3723 · Cited by 625
Patisiran: First Global Approval
Hoy, S. M. (2018) · Drugs · doi:10.1007/s40265-018-0983-6 · Cited by 614
Lipid nanoparticles enabling gene therapies: from concepts to clinical utility
Kulkarni, J. A., Cullis, P. R., & van der Meel, R. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0721 · Cited by 592 · cited 1×
“Lipid based nanoparticles (LNP), being the most clinically advanced, are an attractive alternative gene delivery vehicle due to their modularity and safety profile [8, 9].”
Background
Research works printed but not linked: 1
- Kay C. Retinal Gene Therapies in Clinical Trials A proliferation of clinical trials means hope for patients. Retinal Physician. 2019 3; 16: 36– 40.
Cited by
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 873
Self-citationThe clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Lipids and Lipid Derivatives for RNA Delivery
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E., & Dong, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00244 · Cited by 626
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 331
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Herrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
Self-citationLipid nanoparticles for siRNA delivery in cancer treatment
El Moukhtari, S. H., Garbayo, E., Amundarain, A., Pascual-Gil, S., Carrasco-León, A., Prosper, F., Agirre, X., & Blanco-Prieto, M. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.054 · Cited by 202
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
“In all such cases, benefit can be obtained via the secretion of survival factors delivered in form of gene therapy potentially in combination with gene replacement(Sahel and Roska, 2013).”
BackgroundmRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 177
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
Loughrey, D., & Dahlman, J. E. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00601 · Cited by 173
Research Advances on the Stability of mRNA Vaccines
Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., & Xu, M. (2023) · Viruses · doi:10.3390/v15030668 · Cited by 162
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 154
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 150
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
Patel, S. K., Billingsley, M. M., Frazee, C. P., Han, X., Swingle, K. L., Qin, J., Alameh, M., Wang, K., Weissman, D., & Mitchell, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.020 · Cited by 147
Self-citationGautam, M., Jozic, A., Su, G. L.-N., Herrera-Barrera, M., Curtis, A., Arrizabalaga, S., Tschetter, W., Ryals, R. C., & Sahay, G. (2023) · Nature Communications · doi:10.1038/s41467-023-42189-3 · Cited by 123
Self-citationKong, W., Wei, Y., Dong, Z., Liu, W., Zhao, J., Huang, Y., Yang, J., Wu, W., He, H., & Qi, J. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02812-x · Cited by 143
Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z., & Blakney, A. K. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00032 · Cited by 125
Wu, L., Li, X., Qian, X., Wang, S., Liu, J., & Yan, J. (2024) · Vaccines · doi:10.3390/vaccines12020186 · Cited by 141
Topical Drug Delivery to the Posterior Segment of the Eye
Löscher, M., Seiz, C., Hurst, J., & Schnichels, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010134 · Cited by 123
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors
Anthiya, S., Öztürk, S. C., Yanık, H., Tavukçuoğlu, E., Şahin, A., Datta, D., Charissé, K., Moreira, D., Loza, M. I., Calvo, A., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.016 · Cited by 113
Petersen, D. M. S., Chaudhary, N., Arral, M. L., Weiss, R. M., & Whitehead, K. A. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.006 · Cited by 92
Kawaguchi, M., Noda, M., Ono, A., Kamiya, M., Matsumoto, M., Tsurumaru, M., Mizukami, S., Mukai, H., & Kawakami, S. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.026 · Cited by 86
Zhang, L., Seow, B. Y. L., Ba, K., Zhang, Y., Liao, K., Wan, Y., & Yang, Y. Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.071 · Cited by 94
Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery
Żak, M. M., & Zangi, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101675 · Cited by 79
Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies
Huang, X., Ma, Y., Ma, G., & Xia, Y. (2024) · Research · doi:10.34133/research.0370 · Cited by 96
Sarode, A., Fan, Y., Byrnes, A. E., Hammel, M., Hura, G. L., Fu, Y., Kou, P., Hu, C., Hinz, F. I., Roberts, J., et al. (2022) · Nanoscale Advances · doi:10.1039/d1na00712b · Cited by 82
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 83
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 83
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
Vervaeke, P., Borgos, S. E., Sanders, N. N., & Combes, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114236 · Cited by 70
LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea
Mohanna, S. Z. M., Djaksigulova, D., Hill, A. M., Wagner, P. K., Simpson, E. M., & Leavitt, B. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.042 · Cited by 79
Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics
Vasileva, O., Zaborova, O. V., Shmykov, B., Ivanov, R. A., & Reshetnikov, V. V. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1466337 · Cited by 86
Khalil, A., Barras, A., Boukherroub, R., Tseng, C., Devos, D., Burnouf, T., Neuhaus, W., & Szunerits, S. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00306j · Cited by 64
Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 65
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 59
Labonia, M. C. I., Sentí, M. E., van der Kraak, P. H., Brans, M. A. D., Dokter, I., Streef, T. J., Smits, A. M., Deshantri, A. K., de Jager, S. C. A., Schiffelers, R. M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.018 · Cited by 70
Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues
Eygeris, Y., Gupta, M., Kim, J., Jozić, A., Gautam, M., Renner, J., Nelson, D., Bloom, E., Tuttle, A., Stoddard, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307813120 · Cited by 62
Self-citationLipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 73
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 56
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 77
Deciphering the Role of PEGylation on the Lipid Nanoparticle-Mediated mRNA Delivery to the Liver
Gao, M., Zhong, J., Liu, X., Zhao, Y., Zhu, D., Shi, X., Xu, X., Zhou, Q., Xuan, W., Zhang, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c09399 · Cited by 57
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 72
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 59
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Hakim, A. M., Guido, B., Narsineni, L., Chen, D.-W., & Földvári, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114781 · Cited by 56
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 53
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 97
Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells
Khare, P., Dave, K. M., Kamte, Y. S., Manoharan, M., O’Donnell, L. A., & Manickam, D. S. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00653-2 · Cited by 54
Polysarcosine-based lipid formulations for intracranial delivery of mRNA
Bi, D., Unthan, D., Hu, L., Bussmann, J., Remaut, K., Barz, M., & Zhang, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.021 · Cited by 50
Xie, H., Payne, T. J., Takanashi, A., Fang, Y., Kerai, S. D., Morrow, J. P., Al-Wassiti, H. A., Pouton, C. W., & Kempe, K. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00651 · Cited by 54
Petersen, D. M. S., Weiss, R. M., Hajj, K. A., Yerneni, S. S., Chaudhary, N., Newby, A. N., Arral, M. L., & Whitehead, K. A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400225 · Cited by 47
Chan, C., Du, S., Dong, Y., & Cheng, X. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201126162945 · Cited by 46
Gyanani, V., & Goswami, R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041184 · Cited by 44
Therapeutic synthetic and natural materials for immunoengineering
Slezak, A., Chang, K., Hossainy, S., Mansurov, A., Rowan, S. J., Hubbell, J. A., & Guler, M. O. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00805c · Cited by 46
A robust post-insertion method for the preparation of targeted siRNA LNPs
Swart, L. E., Koekman, A. C., Seinen, C. W., Issa, H., Rasouli, M., Schiffelers, R. M., & Heidenreich, O. T. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121741 · Cited by 43
Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 38
Selvaraj, G., Kaliamurthi, S., Peslherbe, G. H., & Wei, D. (2021) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-021-00438-3 · Cited by 37
Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34
Self-citationAbostait, A., Abdelkarim, M., Bao, Z., Miyake, Y., Tse, W. H., Ciano‐Oliveira, C. D., Buerki‐Thurnherr, T., Allen, C. J., Keijzer, R., & Labouta, H. I. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.047 · Cited by 35
Sohi, A. N., Kiani, J., Arefian, E., Khosrojerdi, A., Fekrirad, Z., Ghaemi, S., Zim, M. K., Jalili, A., Bostanshirin, N., & Soleimani, M. (2021) · Vaccines · doi:10.3390/vaccines9091007 · Cited by 32
ICG-mediated photodisruption of the inner limiting membrane enhances retinal drug delivery
Peynshaert, K., Vanluchene, H., Clerck, K. D., Minnaert, A., Verhoeven, M., Gouspillou, N., Bostan, N., Hisatomi, T., Accou, G., Sauvage, F., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.002 · Cited by 33
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 38
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 36
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 34
The Interplay of Endosomal Escape and RNA Release from Polymeric Nanoparticles
Cheung, T. H., & Shoichet, M. S. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c05176 · Cited by 35
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 44
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 34
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 57
Bohley, M., Dillinger, A. E., Tamm, E. R., & Göpferich, A. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.024 · Cited by 29
Bepperling, A., & Richter, G. M. (2023) · European Biophysics Journal · doi:10.1007/s00249-023-01663-y · Cited by 35
Pharmacokinetics of Pullulan–Dexamethasone Conjugates in Retinal Drug Delivery
Kicková, E., Sadeghi, A., Puranen, J., Tavakoli, S., Sen, M., Ranta, V., Arango‐González, B., Bolz, S., Ueffing, M., Salmaso, S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010012 · Cited by 28
CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders
Cabré-Romans, J.-J., & Cuella-Martin, R. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1553590 · Cited by 38
PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation
Gao, P. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.133 · Cited by 34
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 28
Vasudevan, A., Jozić, A., Curtis, A. G., Bodi, E., Ryals, R. C., & Sahay, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.068 · Cited by 29
Self-citationZhang, Y., Watson, S. L., Ramaswamy, Y., & Singh, G. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103200 · Cited by 28
Qin, Y., Walters, A. A., Rouatbi, N., Wang, J. T.-W., Abdel‐Bar, H. M., & Al‐Jamal, K. T. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122158 · Cited by 28
Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
Li, J., Zhang, Y., Yang, Y., & Sun, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00276 · Cited by 26
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 25
Bellingrath, J.-S., McClements, M. E., Fischer, M. D., & MacLaren, R. E. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1092913 · Cited by 22
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Advances in the study of LNPs for mRNA delivery and clinical applications
Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 22
Stargardt macular dystrophy and therapeutic approaches
Fujinami, K., Waheed, N. K., Laich, Y., Yang, P. G., Fujinami‐Yokokawa, Y., Higgins, J. J., Lu, J. T., Curtiss, D., Clary, C. M., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-323071 · Cited by 38
Bizmark, N., Nayagam, S. K., Kim, B., Amelemah, D. F., Zhang, D., Datta, S. S., Priestley, R. D., Colace, T., Wang, J., & Prud’homme, R. K. (2024) · Advanced Materials Interfaces · doi:10.1002/admi.202301083 · Cited by 30
Liu, J., Xiao, B., Yang, Y., Jiang, Y., Wang, R., Qi, W. D., Pan, Y., Chen, Y., Wang, H., Fan, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06160 · Cited by 24
Poly(2-methyl-2-oxazoline) as a polyethylene glycol alternative for lipid nanoparticle formulation
van Zyl, D. G., Mendes, L. P., Semper, R. P., Rueckert, C., & Baumhof, P. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1383038 · Cited by 25
Duan, Q., Hu, T., Zhu, Q., Jin, X., Chi, F., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974433 · Cited by 21
Lipid nanoparticles for gene therapy in ocular diseases
González, C. C., Saráoz, J. V. M., Roacho-Pérez, J. A., & Olivas-Armendáriz, I. (2023) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-023-00455-1 · Cited by 22
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes
Wang, T., Yu, T., Liu, Q., Sung, T., & Higuchi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102236 · Cited by 22
Vosoughi, P., Naghib, S. M., Kangarshahi, B. M., & Mozafari, M. R. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139532 · Cited by 24
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Hurst, J., Adams, F., & Schnichels, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407173 · Cited by 24
Li, W., Vanluchene, H., Raes, L., Peynshaert, K., Veys, L., Hernández, S. G., Lombaerde, E. D., Geest, B. G. D., Sanders, N. N., Moons, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114027 · Cited by 21
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Metadata
- Authors
- Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G.
- Affiliations
- Oregon Health & Science University (US)
- Oregon State University (US)
- Corresponding author
- Sahay, Gaurav
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-10-29
- Volume
- 15
- Issue
- 10
- Pages
- e0241006
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7595320
- OpenAlex
- W3096490487
- Cited by
- 194
- References
- 40
- Citations by year
- 2026: 30 · 2025: 42 · 2024: 32 · 2023: 37 · 2022: 35 · 2021: 17 · 2020: 1
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P30 EY010572)
- National Eye Institute (1R21EY031066-01A1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- PEGylation, lipid nanoparticles, mRNA delivery, ocular gene therapy, retinal degeneration, subretinal injection, intravitreal injection, retinal pigment epithelium, apolipoprotein E, MERTK, Müller cells, optic nerve head, trabecular meshwork, particle size
- MeSH terms
- Mice, Knockout, ApoE, Red Fluorescent Protein, Animals, Female, Fundus Oculi, Lipids, Luminescent Proteins, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Particle Size, Polyethylene Glycols, RNA, Messenger, Drug Delivery Systems, Gene Transfer Techniques, Nanoparticles, Retinal Pigment Epithelium, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.